#METABOLOMICS WORKBENCH mlee_20170410_151841 DATATRACK_ID:885 STUDY_ID:ST001120 ANALYSIS_ID:AN001832 PROJECT_ID:PR000751
VERSION             	1
CREATED_ON             	January 15, 2019, 9:05 am
#PROJECT
PR:PROJECT_TITLE                 	Lipid Metabolism in Bladder Cancer with Cisplatin Resistance
PR:PROJECT_SUMMARY               	This study conducted comprehensive and comparative lipidomic profiling of two
PR:PROJECT_SUMMARY               	isogenic human T24 bladder cell lines, which are characterized as sensitive or
PR:PROJECT_SUMMARY               	resistant to the cisplatin-induced cell apoptosis.
PR:INSTITUTE                     	Cedars-Sinai Medical Center
PR:DEPARTMENT                    	Departments of Surgery and Biomedical Sciences
PR:LAST_NAME                     	Kim
PR:FIRST_NAME                    	Jayoung
PR:ADDRESS                       	8700 Beverly Blvd., Davis 5071 Los Angeles, CA 90048, USA
PR:EMAIL                         	Jayoung.Kim@cshs.org
PR:PHONE                         	310-423-7168
#STUDY
ST:STUDY_TITLE                   	Reprogrammed Lipid Metabolism in Bladder Cancer with Cisplatin Resistance
ST:STUDY_SUMMARY                 	This study conducted comprehensive and comparative lipidomic profiling of two
ST:STUDY_SUMMARY                 	isogenic human T24 bladder cell lines, which are characterized as sensitive or
ST:STUDY_SUMMARY                 	resistant to the cisplatin-induced cell apoptosis.
ST:INSTITUTE                     	Cedars-Sinai Medical Center
ST:DEPARTMENT                    	Departments of Surgery and Biomedical Sciences
ST:LAST_NAME                     	Kim
ST:FIRST_NAME                    	Jayoung
ST:ADDRESS                       	8700 Beverly Blvd., Davis 5071 Los Angeles, CA 90048, USA
ST:EMAIL                         	Jayoung.Kim@cshs.org
ST:PHONE                         	310-423-7168
ST:STUDY_COMMENTS                	Treatment with ACSS1 inhibitor
#SUBJECT
SU:SUBJECT_TYPE                  	Cell line
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	S-_01	Cell line:T24S | Treatment:No	
SUBJECT_SAMPLE_FACTORS           	-	S-_02	Cell line:T24S | Treatment:No	
SUBJECT_SAMPLE_FACTORS           	-	S+_01	Cell line:T24S | Treatment:Yes	
SUBJECT_SAMPLE_FACTORS           	-	S+_02	Cell line:T24S | Treatment:Yes	
SUBJECT_SAMPLE_FACTORS           	-	R-_01	Cell line:T24R | Treatment:No	
SUBJECT_SAMPLE_FACTORS           	-	R-_02	Cell line:T24R | Treatment:No	
SUBJECT_SAMPLE_FACTORS           	-	R+_01	Cell line:T24R | Treatment:Yes	
SUBJECT_SAMPLE_FACTORS           	-	R+_02	Cell line:T24R | Treatment:Yes	
#COLLECTION
CO:COLLECTION_SUMMARY            	T24 BC cells were obtained and cultured, according to instructions provided by
CO:COLLECTION_SUMMARY            	the ATCC. Media was supplemented with 10% fetal bovine serum, 2% glutamine and
CO:COLLECTION_SUMMARY            	1% antibiotics (Invitrogen, Carlsbad, CA). Cells were maintained under a
CO:COLLECTION_SUMMARY            	humidified atmosphere of 5% CO2 at 37°C. These cell lines were negative for
CO:COLLECTION_SUMMARY            	mycoplasma and all other infectious agents evaluated.
CO:SAMPLE_TYPE                   	Cultured cells
#TREATMENT
TR:TREATMENT_SUMMARY             	T24 BC cells were characterized in our laboratory as cisplatin resistant BC
TR:TREATMENT_SUMMARY             	(T24R, R) or cisplatin sensitive BC cells (T24S, S) to cisplatin-induced
TR:TREATMENT_SUMMARY             	apoptosis.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	We separated lipid extracts from proteins and polar hydrophilic small molecules
SP:SAMPLEPREP_SUMMARY            	in a way where the lipids are found in the top layer of liquid-liquid
SP:SAMPLEPREP_SUMMARY            	separations, rather than in the bottom layer. Decanting the top layer,
SP:SAMPLEPREP_SUMMARY            	therefore, ensured that proteins or polar compounds did not contaminate
SP:SAMPLEPREP_SUMMARY            	extracts.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Waters Acquity CSH C18 (100 x 2.1mm, 1.7um)
CH:COLUMN_NAME                   	particles)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6530 QTOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	none
MS:MS_RESULTS_FILE               	ST001120_AN001832_Results.txt	UNITS:normalized_intensity	Has m/z:Yes	Has RT:Yes	RT units:Minutes
#END